Clinical Trial Update: Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ORM-12741 for preventing Raynaud's phenomenon was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon

Drugs mentioned

• ORM-12741

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Raynaud's Phenomenon | Phase 2 | Status: TERMINATED